Group 1 - The core announcement is regarding the judicial freeze and subsequent release of shares held by a major shareholder of the company, Shenzhen Bo Heng Investment Co., Ltd. [1] - On June 10, 2025, the company disclosed that a total of 15,114,647 shares held by Bo Heng Investment were frozen by the Hangzhou Intermediate People's Court in Zhejiang Province [1] - Recently, the company confirmed through the China Securities Depository and Clearing Corporation Limited Shenzhen Branch that the aforementioned shares have been released from judicial freeze [1]

Group 1 - Fulin Precision's subsidiary Jiangxi Shenghua invested 270 million yuan to establish a joint venture for a 500,000-ton ferrous oxalate project, with a total investment of 1.5 billion yuan expected to be completed by September 30, 2026 [1] - Xuguang Electronics plans to raise up to 1 billion yuan through a private placement to fund high-voltage vacuum arc extinguishing chamber expansion and other projects [2] - Minexplosion Optoelectronics intends to acquire 100% equity of Xiazhi Precision, with the transaction subject to shareholder and regulatory approvals [3] Group 2 - Shangluo Electronics' controlling shareholder plans to reduce his stake by up to 3% due to personal financial needs [4] - Babi Food reported a 1.3% decline in net profit for 2025, despite an 11.22% increase in revenue [5] - Pengding Holdings' subsidiary acquired industrial land in Huai'an for 66.14 million yuan [6] Group 3 - Zhuoyue New Energy's net profit for 2025 increased by 14.16%, despite a 17.43% decline in revenue [7] - Zhongyuan Media's net profit grew by 30.99% in 2025, with revenue decreasing by 5.13% [8] - Huangshan Tourism plans to invest approximately 530 million yuan in a hotel project with a 24-month construction period [9] Group 4 - *ST Jinling's restructuring plan was approved by the court, which may improve the company's financial situation [11] - Jichuan Pharmaceutical's subsidiary paid 80 million yuan for exclusive commercialization rights of a drug [12] - Pilin Bio's subsidiary received a notice for the acceptance of a drug supplement application [13] Group 5 - Nepe Mining terminated its investment in Swiss Veritas Resources AG due to changes in conditions [14] - Jinhui Wine announced a cash dividend of 0.20 yuan per share for the first three quarters of 2025 [15] - Hualan Biological's clinical trial for a new drug received approval for an additional indication [16] Group 6 - Industrial Fulian reported a total of 247 million yuan spent on share buybacks as of January 31, 2026 [17] - Yitong Century was pre-selected for a 107 million yuan project with China Tower [18] - Wanfeng Co. noted uncertainty in future price changes for disperse dyes [19] Group 7 - Bibet's clinical trial application for a new drug was approved by the National Medical Products Administration [21] - Chengbang Co. signed new project contracts worth 40.03 million yuan in Q4 2025 [22] - *ST Hengji received a court ruling for a performance compensation of 175 million yuan [23] Group 8 - Jihua Group is planning a change in control, leading to continued stock suspension [24] - Ningbo Port expects a container throughput of 5.03 million TEUs in January 2026, a 9.5% increase [25] - Hengli Petrochemical's actual controller increased his stake by 3.3 million shares [26] Group 9 - Hongfuhan signed a sales contract worth 480 million yuan with Guangdong Quanxiang [27] - All New Good's shareholder lifted a judicial freeze on 4.36% of the company's shares [28] - Changchun High-tech's subsidiary's clinical trial application for a new drug was accepted [29] Group 10 - Xingqi Eye Medicine's clinical trial for a new drug entered the first/second phase [31] - Hanma Technology reported a 140.04% increase in new energy heavy truck production in January 2026 [32] - Hengfeng Paper plans to invest 349 million yuan in a new green printing project [33] Group 11 - Zhifei Biological's mRNA vaccine for shingles received clinical trial approval [34] - Yutong Bus reported a 15.35% decrease in production in January 2026 [35] - StarNet Ruijie plans to sign a lease contract with an affiliate for a total rent of up to 110 million yuan [36] Group 12 - Hacheng Bonda's director completed a 0.97% share reduction [37] - Hendi Pharmaceutical's application for a new drug was approved [38] - Xinhua Medical's subsidiary received a medical device registration certificate [40] Group 13 - Yaokang Bio reported a 31.49% increase in net profit for 2025 [41] - Gaotie Electric reported a 14.02% increase in net profit for 2025 [42]

深圳市全新好股份有限公司（以下简称"公司"或"全新好"）于 2025 年 6 月 10 日披露了《关于公司持股 5%以上股东所持公司股份被司法冻结的公告》 （公告编号：2025-017），公司股东深圳市博恒投资有限公司（以下简称"博恒 投资"）所持公司股票合计 15,114,647 股被浙江省杭州市中级人民法院司法冻 结。 近日，公司通过中国证券登记结算有限责任公司深圳分公司系统查询，股东 博恒投资所持公司股票合计 15,114,647 股已解除司法冻结，具体事项如下： 一、股东股份解除冻结的基本情况 证券代码：000007 证券简称：全新好 公告编号:2026—004 深圳市全新好股份有限公司 关于公司持股 5%以上股东所持公司股份解除冻结的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 二、对公司的影响及风险提示 前述股东所持公司股票解除司法冻结的情况不会导致控制权发生变更，亦未 对公司日常经营管理造成影响。 公司指定的信息披露媒体为《证券时报》、《证券日报》、《中国证券报》、 《上海证券报》和巨潮资讯网（www.cninfo.com.cn），公司所 ...

Group 1 - The core point of the article is that Shenzhen Bo Heng Investment Co., Ltd. has lifted the freeze on 15.1146 million shares of the company, which accounts for 4.36% of the total share capital [1]

Group 1 - The company expects a negative net profit for the fiscal year 2025, covering the period from January 1, 2025, to December 31, 2025 [1] - The estimated loss is primarily due to a provision for expected liabilities related to litigation and arbitration amounting to 8.723 million yuan [1] - The financial data presented is a preliminary estimate from the company's finance department and has not been reviewed by the accounting firm, although initial communication has occurred without major disagreements [1]

Core Viewpoint - The company expects a loss of 3.7 million to 5.5 million yuan in 2025, indicating a shift from profit to loss compared to the previous year [1] Financial Performance - The net profit, excluding non-recurring gains and losses, is projected to be between 2.7 million and 4 million yuan, representing a decline of 70.03% to 55.60% year-on-year [1] - The primary reason for the performance change is the provision for expected liabilities of 8.723 million yuan related to litigation and arbitration cases [1]

Group 1 - The company, All-New Good, announced an earnings forecast on January 27, expecting a net loss attributable to shareholders of 3.7 million to 5.5 million yuan for 2025, compared to a profit of 56.42 million yuan in the same period last year [1] - The basic earnings per share are projected to be a loss of 0.0107 to 0.0159 yuan [1] Group 2 - International gold prices have surpassed 5,000 dollars, marking a 280% increase over the past seven years [1] - Experts suggest that the key factors influencing gold prices include the performance of the US dollar, the international monetary system, interest rate cuts, and technological revolutions [1]

Core Viewpoint - The company expects a significant net loss for the year 2025, primarily due to legal arbitration costs impacting profitability [1] Financial Performance - The net profit attributable to shareholders is projected to be a loss of 3.7 to 5.5 million yuan, compared to a profit of 56.42 million yuan in the same period last year [1] - The net profit after deducting non-recurring gains and losses is expected to be between 2.7 to 4 million yuan, representing a year-on-year decline of 70.03% to 55.60% [1] - The basic earnings per share are anticipated to be a loss of 0.0107 to 0.0159 yuan per share, down from a profit of 0.1629 yuan per share in the previous year [1] Key Factors - The primary reason for the performance change is the provision for expected liabilities related to litigation and arbitration amounting to 8.723 million yuan [1]

Financial Performance Forecast - The company expects a net profit loss between 3,700 to 5,500 thousand yuan for the year 2025, compared to a profit of 5,642.17 thousand yuan in the previous year[4]. - The net profit after deducting non-recurring gains and losses is projected to be between 2,700 to 4,000 thousand yuan, reflecting a decline of 70.03% to 55.60% compared to the previous year's profit of 900.88 thousand yuan[4]. - Basic earnings per share are expected to be a loss of 0.0107 to 0.0159 yuan per share, down from a profit of 0.1629 yuan per share in the previous year[4]. Reasons for Performance Change - The primary reason for the performance change is the provision for expected liabilities related to litigation and arbitration amounting to 8,723 thousand yuan[6]. Financial Data and Review Status - The financial data presented is a preliminary estimate by the company's finance department and has not been reviewed by the accounting firm[5]. - The company has communicated with the accounting firm regarding the performance forecast, and there are no significant discrepancies between the two parties[5]. - The specific financial data will be detailed in the company's 2025 annual report[7]. Investment Risks - The company warns investors to pay attention to investment risks associated with the preliminary nature of the performance forecast[7].

Group 1 - The stock of All New Good increased by 5.74%, closing at 12.16 yuan on January 8 [1] - A block trade occurred with a total volume of 15,322,200 shares and a transaction amount of 159 million yuan [1] - The first transaction price was 10.35 yuan, with a total of 15,322,200 shares traded, resulting in a transaction amount of 158.58 million yuan and a premium rate of -14.88% [1] Group 2 - In the last three months, the stock has recorded two block trades with a total transaction amount of 164 million yuan [1] - Over the past five trading days, the stock has risen by 4.65%, while the net outflow of main funds totaled 4.84 million yuan [1]